DISCOVER SYLENTIS
Media
If you need to contact our communication department, please do it by contacting:
- Lara Vadillo Muñoz
- Miriam Collados Gordo
- Pharma Mar Communication Dept.
- Phone: +34 91 846 6000
Press releases
Sylentis, a PharmaMar Group company, announces the positive results of the Phase IIa dose-ranging study for SYL1801 in patients with Age-Related Macular Degeneration (AMD)
The primary endpoint was reached, a mean gain from baseline was observed in a middle [...]
Sylentis, a PharmaMar Group company, announces the FYDES study to evaluate the safety of tivanisiran in patients with dry eye disease has met its primary endpoint
FYDES achieved the primary endpoint of the study by demonstrating the long-term safety of tivanisiran [...]
18
Dec
Dec
Sylentis, a PharmaMar Group company, begins a new Phase II trial with SYL1801 for patients with Age-Related Macular Degeneration
Madrid, November 23rd, 2022. – Sylentis, a PharmaMar Group Company (MSE:PHM), has announced today the [...]
23
Nov
Nov
Sylentis, a wholly owned subsidiary of PharmaMar, inaugurates first oligonucleotide manufacturing plant in Spain
The plant, which has a surface area of 400m2, will serve both Sylentis’ manufacturing needs [...]
19
Apr
Apr
Sylentis initiates a new Phase III trial in the United States to evaluate the safety of tivanisiran in patients with dry eye disease
This Phase III study, called FYDES, will involve 26 hospitals in the United States. It [...]
01
Apr
Apr
Sylentis, PharmaMar Group, completes Phase I trial with SYL1801 for retinal diseases
This trial involved 36 healthy volunteers who were administered eye drops for the treatment and/or [...]
14
Mar
Mar
Sylentis, PharmaMar Group, initiates a Phase I clinical trial with SYL1801 for retinal diseases
This Phase I trial will enroll 36 healthy volunteers and will be conducted at the [...]
18
Mar
Mar
The World Health Organization selects tivanisiran as the International Nonproprietary Name for SYL1001
Tivanisiran is under investigation in a Phase III clinical trial, HELIX, in more than 30 European hospitals and 300 patients to determine its efficacy in dry eye syndrome Madrid, October 19th, 2017.- Sylentis, a Pharmaceutical Company [...]
Sylentis, a pioneer in RNAi technology, obtains authorisation as research drug manufacturing laboratory
Sylentis, a biopharmaceutical company in Grupo Zeltia (MC:ZEL) which is a pioneer in the research and development of new drugs based on gene silencing (interference RNA: RNAi) and one of the four companies in the world with [...]
Sylentis, a PharmaMar Group company, appoints Andreas Segerros as Chief Executive Officer
Sylentis, a wholly owned subsidiary of PharmaMar (MSE:PHM), has appointed Andreas Segerros as Chief Executive Officer (CEO). This new appointment aims to redirect Sylentis’ strategic direction with an independent management from PharmarMar. Andreas brings a wealth of [...]
Zeltia subsidiary Sylentis commences Phase I trials with its new compound SYL1001 to treat eye pain associated with dry eye syndrome
SYL1001 is a new compound arising from Sylentis’s research in ophthalmological disorders It is indicated for treating eye discomfort associated with dry eye syndrome SYL1001 is a form of interference RNA (RNAi) SYL1001 inhibits [...]
Sylentis announces results of Phase 3 HELIX trial with tivanisiran for the treatment of Dry Eye Disease
The HELIX trial has shown improvement (p=0.035) in the reduction of central corneal staining Data will be presented to the FDA and other regulatory authorities during the second quarter of 2019 to define the regulatory strategy The [...]
Sylentis announces the clinical results of tivanisiran for the treatment of dry eye syndrome
The studies carried out with tivanisiran showed an improvement in the inflammatory ocular parameters, tear quality, and a reduction in ocular pain, that is associated with dry eye syndrome Madrid, May 3rd, 2018. Sylentis, Pharmaceutical Company [...]
Sylentis announces top-line results from Phase II study SYLTAG for RNAi drug bamosiran (SYL040012) in Glaucoma
All bamosiran doses similarly reduced the intraocular pressure (IOP). In patients with a baseline IOP greater than or equal to 25 mm Hg, 1.125% bamosiran showed more efficacy The trial did not meet the secondary objective of [...]
Sylentis initiates a Phase III study for the treatment of dry eye syndrome
HELIX is a Phase III clinical trial started by Sylentis with the investigational new drug SYL1001, based on RNA interference technology (RNAi). The Company has agreed with the U.S. Food and Drug Administration (FDA) on plans for [...]
Sylentis participates in the 7th Spanish Conference on Glaucoma (SEG)
Madrid, 9 March 2011: Sylentis (MC:ZEL) presented the main results of its Phase I trial on safety and tolerance of its product SYL040012; the compound proved to be safe in the trial conditions. These results were presented in an [...]
